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ABSTRACT 
 
ROLE OF INTERLEUKIN-17 IN THE ADAPTIVE 
 IMMUNE RESPONSE IN LYME ARTHRITIS 
by 
 
Emily M. Siebers 
 
The University of Wisconsin-Milwaukee, 2012 
Under the Supervision of Dr. Dean T. Nardelli 
 
 
Lyme arthritis is a devastating symptom of Lyme borreliosis that causes severe 
inflammation of the synovial joints. Interleukin-17 (IL-17) plays a role in the 
pathogenesis of various arthritides, including, possibly, Lyme arthritis, by causing 
the expression of genes involved in the production of inflammatory cytokines by 
synoviocytes. However, the cellular sources of IL-17 in the context of Borrelia 
burgdorferi infection are unknown, as are the effects of these cells on the 
development of arthritis and stimulation of humoral immunity through the 
production of borreliacidal antibodies. Using multiple models of Lyme arthritis, the 
hypothesis that IL-17 produced by CD4+ cells contributes to the inflammation 
associated with B. burgdorferi infection and is associated with an increase in 
borreliacidal antibody production was tested. Serum IL-17 levels were increased 
during Borrelia infection, especially at the time of peak swelling. Neutralization of 
interferon-gamma increased these IL-17 levels, and the addition of anti-CD4 
antibodies to cultures of stimulated cells isolated during peak swelling reduced 
IL-17 levels. In addition, a role for IL-10 in the production of IL-17 was 
demonstrated. Furthermore, increased IL-17 was associated with an increase of 
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borreliacidal antibodies. These findings suggest CD4+ cells (possibly T cells) 
contribute to the production of IL-17 following infection with B. burgdorferi and 
that levels of this cytokine may affect borreliacidal antibody production.  
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CHAPTER 1: INTRODUCTION 
I. Background 
1. Lyme Borreliosis 
Lyme borreliosis is the most common tick-borne disease in the United States, 
affecting tens of thousands of Americans infected with the spirochete Borrelia 
burgdorferi annually (1). It is a multi-stage, multi-symptom disease that is often 
misdiagnosed due to its vague clinical presentation. The main manifestations of 
Lyme borreliosis involve the neurological, cardiovascular, and musculoskeletal 
systems, with symptoms increasing in severity in the absence of antimicrobial 
therapy. However, a small proportion of genetically predisposed individuals 
continue to exhibit symptoms despite receiving, in accordance with guidelines 
established by experts in the field, antimicrobial therapy considered sufficient for 
clearing infection (2, 3). The cause of these persistent, chronic symptoms is a 
source of great contention in the field; among the most frequently considered 
theories are survival of the microbe in connective tissues, retention of antigenic 
microbial fragments, and infection-induced autoimmunity (4). Regardless, the 
pathology of Lyme borreliosis is caused by the immune response to infection, as 
B. burgdorferi does not secrete toxins or other products that induce tissue 
damage. Therefore, in the absence of effective antimicrobial treatment, anti-
inflammatory therapeutic interventions would be a significant means for reducing 
morbidity of Lyme borreliosis. 
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Lyme borreliosis is endemic to several regions of the United States, including the 
Northeast, Mid-Atlantic, Upper Midwest, and Far West. Lyme borreliosis is 
transmitted by the bite of the Ixodes tick and is endemic to regions in which these 
tick vectors, as well as their animal reservoirs, live. In the northeastern and upper 
midwestern United States, B. burgdorferi is transmitted to humans by I. 
scapularis. These ticks become infected with the spirochete when they take a 
blood meal from infected small rodents (typically mice) and other mammalian 
hosts, such as deer and foxes. In the western United States, lizards occasionally 
serve as a reservoir for the bacteria (5) and are transmitted via I. pacificus. 
Moreover, birds have been identified as carriers of B. burgdorferi, providing a 
means for the bacteria to spread farther distances (6). Transmission most 
commonly occurs during the nymphal stage of tick development, when they are 
relatively small and are difficult to observe (2). The greatest onset of illness 
occurs between the months of May and August, when ticks have reached this 
stage of development. Though relatively rare, adult ticks are also capable of 
causing infection (2). In endemic areas, up to 30% of Ixodes ticks may be 
infected (7). An infected tick must be attached to its host for several days in order 
to transmit B. burgdorferi effectively (8). Unfortunately, patients diagnosed with 
Lyme borreliosis often do not recall having been bitten by a tick. 
 
2. Stages of Disease, Diagnosis, and Therapeutic Measures 
Untreated Lyme borreliosis is characterized by three phases: early infection, 
disseminated infection, and late infection. Most early symptoms of Lyme 
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borreliosis are typically vague, presenting as flu-like symptoms such as fever, 
headache, fatigue, and joint and muscle aches one to two weeks after the bite of 
an infected tick. However, diagnosis in this early stage is facilitated greatly by a 
skin lesion called erythema migrans (EM). EM is a painless, flat rash that 
radiates from the site of the tick bite and often exhibits central clearing, 
resembling a bull’s-eye. Approximately 70% of infected individuals develop EM 
and, when it is observed in an endemic area or following a known tick bite, it is 
usually considered diagnostic (2). However, due to the rash’s varied appearance 
and occasionally inconspicuous anatomical location, EM is often not observed by 
the patient or physician. Moreover, since the other symptoms of this early phase 
are constitutional, a diagnosis of Lyme borreliosis frequently is not considered 
and the infection progresses without treatment.  
 
The second stage of Lyme borreliosis involves dissemination throughout the 
body weeks to months after infection and manifests in more severe symptoms. 
Secondary EM lesions are commonly observed at locations distal from the site of 
infection (2). Atrioventricular block, as well as neurological abnormalities such as 
numbness or tingling of the extremities, visual disturbances, and partial paralysis 
of facial muscles (9, 10), are commonly observed. Patients frequently develop 
more pronounced musculoskeletal symptoms, including pain and swelling of the 
joints and tendons (2). These symptoms may be exacerbated in late, persistent 
Lyme borreliosis, which occurs months to years after the initial onset of disease. 
Patients may experience profound neurological symptoms, including memory 
loss, fluctuations in mood, and peripheral neuropathy. In addition, 60% of 
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infected individuals at this stage exhibit Lyme arthritis, which is characterized by 
severe inflammation of the synovial tissues, ligaments, and tendons (2). Despite 
antimicrobial treatment, some individuals develop a chronic, severe, destructive 
arthropathy characterized by erosion of cartilage and bone (11). 
 
Although frequently severe, most of the symptoms of Lyme borreliosis are shared 
by numerous other conditions and, therefore, often confound physicians and 
patients. Difficulties in diagnosis are compounded by the fact that suspected 
cases must fit several criteria before they are accepted as actual cases of 
disease. For example, in the absence of serodiagnostic confirmation, the EM 
lesion must be at least 5 centimeters in diameter and be accompanied by at least 
one late manifestation of disease (12). Current laboratory standards call for 
serodiagnostic confirmation using a two-tiered system: a screening enzyme-
linked immunosorbent assay (ELISA), followed by a confirmatory Western blot 
that is deemed positive based on observation of immunoglobulin M or 
immunoglobulin G antibodies against a certain number of borrelial antigens (3). 
The infection can be cleared with antibiotics; the current standard of treatment is 
two to three weeks of oral doxycyline (3). However, in cases of prolonged 
infection or more severe symptoms, intravenous ceftriaxone may be prescribed 
(3). Subsequent or longer treatments may be needed if the symptoms persist 
beyond the initial course of antibiotics. Delayed treatment increases the 
likelihood of developing chronic symptoms, such as Lyme arthritis. 
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3. Lyme Arthritis 
Lyme arthritis is among the most common clinical manifestations of Lyme 
borreliosis, affecting approximately 60% of individuals infected with B. burgdorferi 
(2). In humans, intermittent episodes of arthritis typically begin in the weeks or 
months following infection and may continue for years. Antibiotic treatment 
typically leads to successful resolution of disease; however, for a small subset of 
patients, arthritis persists despite several courses of antibiotics and negative 
polymerase chain reaction results from synovial tissue and fluid (13). These 
patients, who continue to have proliferative synovitis, are said to have antibiotic-
refractory, or slow-resolving, arthritis (13). In addition to slower resolution of joint 
inflammation, patients with antibiotic-refractory Lyme arthritis also have higher 
levels of pro-inflammatory cytokines and lower levels of anti-inflammatory 
cytokines in the synovial fluid during the entire course of disease, including after 
treatment, when compared to patients with antibiotic-responsive Lyme arthritis 
(14, 15).   
 
Despite a well-defined clinical course, the immune mechanisms responsible for 
the development and persistence of Lyme arthritis are not fully understood.  As a 
result, very few treatment options exist. After antibiotic therapy has been used to 
clear the spirochete infection, the current recommended therapy is the use of 
non-steroidal anti-inflammatory agents (3). Understanding the immune 
mechanisms involved during the course of arthritis, as well as during the course 
of bacterial infection, is essential for the development of novel treatments.   
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4. Innate Immune Events of Lyme Arthritis 
Several innate immune cells are responsible for both the inflammatory response 
observed in early-stage disease and the initial containment of B. burgdorferi. Due 
to the microbe’s ability to bind to various connective tissues (11, 16), an 
inflammatory response is often observed in sites such as the skin, ligaments, 
tendons, and synovial tissues. Large numbers of macrophages and dendritic 
cells, but not neutrophils, are present in the primary EM rash, which is the 
location of initial infection in the skin (17). Interaction of macrophages with B. 
burgdorferi has been shown to cause the production of several inflammatory 
molecules, including interleukin-1-beta (IL-1β), interleukin-6 (IL-6), tumor 
necrosis factor-alpha (TNF-α), and nitric oxide (18). Macrophages are likely 
activated via Toll-like receptor 2, which binds to the lipoproteins found on the 
surface of B. burgdorferi (19). In addition, macrophages and dendritic cells are 
significant activators of the adaptive immune response to B. burgdorferi. 
 
In addition, neutrophils play a major role in the inflammatory response to B. 
burgdorferi. Activation of these cells by B. burgdorferi also causes the production 
of IL-1β and TNF-α (3, 20). Importantly, these cells are found in large numbers in 
the synovial tissues of infected patients (4) and are known producers of the 
inflammatory cytokine interleukin-17 (IL-17) (21). Moreover, natural killer (NK) 
cells, through the production of interferon-gamma (IFN-γ), have been shown to 
contribute to pathology in both C3H and C57BL/6 mice (22, 23), the most 
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commonly used animal models for Lyme arthritis. However, NK cells may not be 
completely required for disease to develop, since their removal in infected mice 
did not reduce the severity of arthritis (22, 23). 
 
These innate inflammatory mediators play a significant role in the initial response 
to the spirochete and the early events of Lyme arthritis. It is imperative to identify 
novel therapies to minimize inflammation at this early stage without disrupting the 
ability of the immune response to contain the infection.  
 
5. T Cell Involvement in Lyme Arthritis 
 
While innate immunity is involved in early pathology, the later-stage events 
observed in humans, typically months to years after infection, involve events of 
adaptive immunity. Synovial lesions in patients with Lyme arthritis contain T 
helper cells with B cells intermixed (24). Due to their predominant presence in 
synovial lesions, T cells have long been investigated as a contributor to Lyme 
arthritis. Traditionally, later-stage Lyme arthritis has been considered to be 
caused by the inflammatory effects of type 1 T helper (Th1) cells and their 
signature cytokine, IFN-γ (25, 26, 27). Increased numbers of Th1 cells and levels 
of IFN-γ have been observed in the synovial tissue, synovial fluid, and peripheral 
blood of humans with Lyme arthritis (28, 29, 30). Th1 cells and IFN-γ are also 
present in experimental mice that develop Lyme arthritis after infection with B. 
burgdorferi (25).  
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However, studies using mice genetically deficient in IFN-γ, its receptor, or its 
signaling pathway have demonstrated that the cytokine is not absolutely required 
for the development of Lyme arthritis (29, 30, 31). Still, T helper cells are involved 
in disease, since animals depleted of CD4+ T cells before infection with B. 
burgdorferi develop minimal inflammatory changes (32). Conversely, transfer of 
Borrelia-primed CD4+ T cells into recipient mice increases pathology following 
infection (33). Collectively, these results suggest that CD4+ T cell-associated 
inflammatory factors in addition to IFN-γ may contribute to the pathogenesis of 
Lyme arthritis. 
 
Another subset of helper T cell, type 17 T helper (Th17) cells, are characterized 
by production of the inflammatory cytokine IL-17 (34) and may also contribute to 
the development of Lyme arthritis. Production of IL-17 is stimulated by borrelial 
lipoproteins (35) and induces other cells to generate a cascade of inflammatory 
mediators capable of damaging host tissue, including that observed in chronic 
arthritis. The inflammatory capacity of IL-17 is demonstrated by its stimulation of 
IL-6, IL-1β, TNF-α, and prostaglandins from various cell types, as well as by its 
role in contributing to collagenase activity and osteoclast formation (36). IL-17 is 
an important mediator of several arthritides, including rheumatoid arthritis (37), 
juvenile idiopathic arthritis (38), antigen-induced arthritis (39), and collagen-
induced arthritis (CIA) (40). Th17 cells play a major role in the development of 
autoimmunity, in part due their production of interleukin-21 (IL-21), which may act 
in a positive feedback loop to maintain a Th17 response (41). Th17 cells also 
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play a significant role in the immune response against fungal and bacterial 
pathogens (42).  
 
Research has suggested that Th17 cells play a potentially pathogenic role 
following infection with B. burgdorferi. Neutralization of IL-17 in B. burgdorferi-
infected mice reduces paw swelling and prevents arthritis (43). In addition, 
simultaneous neutralization of IL-6 and transforming growth factor-β (TGF-β), the 
major differentiation factors for Th17 cells in vitro (44), protects mice from Lyme 
arthritis (45). Moreover, borrelial antigens induce dendritic cells to secrete 
interleukin-23 (IL-23) (46), the major survival factor for Th17 cells (44).          
Neutralization of IL-23 prevents the development of Lyme arthritis in B. 
burgdorferi-infected mice and reduces the production of IL-17 from stimulated 
immune cells (47). Furthermore, borrelial lipoproteins stimulate the in vitro 
production of IL-17 from T cells isolated from the synovia of humans with Lyme 
arthritis (48), and Th17 cells have been isolated directly from such individuals 
(28). However, the direct role of these cells in mediating pathology has not been 
determined. Significantly, it was shown that neutralization of IL-17 in a mouse 
model of Lyme arthritis, in addition to preventing the development of arthritis, 
also resulted in an increase in the number of CD4+CD25+ T cells with 
immunoregulatory function (49). 
 
Current research suggests a role for not just one, but several types of T cells in 
Lyme arthritis. As a result, interactions between the cell types may be involved in 
the development of disease. For example, Th1 and Th17 cells display an 
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antagonistic relationship (50). Through the production of IFN-γ, Th1 cells inhibit 
the proliferation of Th17 cells (50). Likewise, Th17 cells inhibit Th1 cells via the 
production of IL-17 (50). However, despite the ability to counter-regulate each 
other, Th17 and Th1 cells can also display a cooperative relationship. Th17 cells 
can develop into a Th1-like cell (51) and have been shown to produce IFN-γ in 
response to an infectious stimulus (52). The relationship between these two cell 
types may influence the cytokine profile that leads to the development of arthritis. 
This altered cytokine profile occurs in CIA-resistant mice, which have a higher 
ratio of IL-17 to IFN-γ than CIA-susceptible mice (53).  
 
The developmental relationships of these T cells are not straightforward. For 
instance, Th1 cells also influence the development of regulatory T (Treg) cells. 
IFN-γ, produced by Th1 cells, is involved in the conversion of CD4+CD25- helper 
T cells into CD4+Foxp3+ Treg cells via an increase in Foxp3 expression (54). 
Also, Th17 cells may produce interleukin-10 (IL-10), an anti-inflammatory 
cytokine typically produced by Treg cells (52). Taken together, these findings 
suggest an intertwined role of multiple T cell types in the development of Lyme 
arthritis that may be dependent on the cytokine profile expressed following 
infection with B. burgdorferi.   
 
6. Animal Models of Lyme Arthritis 
Traditionally, Lyme arthritis has been studied using C3H mice, which are 
considered genetically “arthritis susceptible” (55) following needle infection with 
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particularly virulent strains of B. burgdorferi (56). In this model, the arthritis that 
ensues manifests days after infection and primarily involves inflammatory events 
of innate immunity. However, Lyme arthritis in humans develops weeks to years 
following infection, suggesting that adaptive immunity plays a significant role in 
disease. In support of this, synovial fluid of human Lyme arthritis patients 
contains CD4+ T cells specific for the likely arthrogenic borrelial antigen outer 
surface protein A (OspA) (57). This finding provides support that cells of adaptive 
immunity–specifically, T cells–are significant contributors to human Lyme 
arthritis. A murine model of Lyme arthritis–the Borrelia-vaccination and -infection 
model–incorporates the activity of primed and activated T cells in inducing 
disease, which is observed in humans with later-stage Lyme arthritis. 
  
Mice are vaccinated with heat-killed B. burgdorferi in aluminum hydroxide in 
order to prime T cells. Three weeks later, they are infected with a heterologous 
strain of Borrelia that is capable of inducing activation of vaccine-primed T cells 
while evading the protective antibody response generated by vaccination. This 
model exhibits an antigen-specific reaction to viable Lyme spirochetes (58, 59) 
and is dependent on CD4+ T cells (33). Infection with homologous spirochetes 
induces arthritis if infection occurs prior to development of protective antibodies 
(59). However, infection with a heterologous strain allows for a degree of 
pathology more suitable for recognition of the effects of immune modulators such 
as anti-cytokine antibodies. A homologous infection strain can also cause arthritis 
following vaccination, as long as infection occurs after the vaccine-induced 
protective antibody response has declined sufficiently. However, this may take as 
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long as two months (60) and could vary between individual animals. In addition to 
reflecting events of adaptive immunity, another benefit of this model is that 
different combinations of Lyme spirochetes can be used for vaccination and 
infection. Also, this model can induce arthritis in C57BL/6 mice, which are 
considered “genetically resistant” to developing arthritis following infection with B. 
burgdorferi, as observed in the Borrelia-infection model (23). 
 
7. Borreliacidal Antibody Response 
An antibody response is required for eliminating B. burgdorferi and resolving the 
inflammatory response following infection. In particular, antibodies with the ability 
to specifically recognize and stimulate killing of the infecting borrelial strain–
borreliacidal antibodies–are considered vital to the clearance of the spirochete 
(61). Early studies showed that injection of serum from B. burgdorferi-infected 
rabbits was able to protect against establishment of infection in hamsters (62). It 
was then shown that injection of Borrelia-immune serum after infection protected 
hamsters from developing arthritis (63). Stimulation of high levels of borreliacidal 
antibodies that are maintained for long periods of time are required for effective 
vaccines against Lyme borreliosis (64). In the mid-1990s, human trials of Lyme 
vaccines required patients to receive three doses of OspA (65, 66). While the 
vaccine was effective against infection during the observation period of the study, 
concerns were raised about the vaccine’s ability to prevent late-stage 
manifestations of disease. The reports of these human trials did not describe for 
how long high borreliacidal antibody titers lasted, and this uncertainty may have 
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contributed to the removal of the Lyme vaccine from the marketplace (64). A 
reliable assay to detect borreliacidal antibody activity is well established (67). 
 
Borreliacidal antibodies against an antigen differ from total antibodies against 
that antigen in important ways. Padilla, et al. (60) showed that humans 
vaccinated with OspA produced borreliacidal antibodies that waned within weeks. 
However, the titers of total antibodies directed against OspA remained high for 
months (60). This difference highlights the importance of identifying factors that 
sustain borreliacidal antibody production, as life-long protective immunity does 
not develop after B. burgdorferi infection. It has also been shown that 
borreliacidal antibody titers decrease as arthritis resolves, indicating a possible 
relationship between arthritis-inducing inflammatory cytokines and the antibody 
response (61). In addition, levels of borreliacidal antibodies decrease as B. 
burgdorferi is cleared from tissues, suggesting that borreliacidal antibodies may 
serve as an indicator of the state of infection (68). This suggests that immune 
factors which increase the borreliacidal antibody response may be useful as a 
therapy against infection with B. burgdorferi.  
 
 
II. Hypothesis and Specific Aims 
Arthritis is a major symptom of Lyme disease, causing inflammation and, in some 
cases, degradation of the synovial joints. A role for IL-17 in the development of 
experimental Lyme arthritis has been established. IL-17 also plays a role in the 
pathogenesis of various arthritides by stimulating the expression of genes 
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involved in the production of inflammatory cytokines, specifically in synoviocytes. 
However, while Th17 cells have been shown to produce IL-17 in response to 
exposure with B. burgdorferi in vitro, it is currently unknown whether T cells are 
the primary cellular source of IL-17 that mediates inflammation. In addition, the 
effects of IL-17 modulation on the stimulation of humoral immunity require further 
examination. The overall objective of this study is to elucidate the contributions of 
IL-17-producing CD4+ cells in the development of B. burgdorferi-induced arthritis 
and IL-17 in the stimulation of the borreliacidal antibody response. Identifying 
sources of IL-17 in Lyme arthritic mice may help reveal immune mechanisms that 
drive the pathogenesis of disease and may lead to identification of novel 
therapeutic targets. Furthermore, understanding the effect of IL-17-producing 
cells on induction of borreliacidal antibodies is essential for the development of 
safe vaccines that provide protection against B. burgdorferi infection. 
 
The hypothesis of this thesis is: IL-17 produced by CD4+ cells contributes to the 
inflammation associated with B. burgdorferi infection and is associated with an 
increase in borreliacidal antibody production.  
 
The following specific aims are pursued to test this hypothesis:  
 
1. Establish CD4+ cells as a source of IL-17 following infection with B. 
burgdorferi. The working hypothesis of this aim is: CD4+ cells are a    
significant source of IL-17 during B. burgdorferi-induced inflammation. 
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2. Establish a relationship between IL-17 levels and borreliacidal 
antibody production. The working hypothesis of this aim is: Increases in    
IL-17 are associated with an increase in borreliacidal antibody titers 
following infection with B. burgdorferi. 
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CHAPTER 2: MATERIALS AND METHODS 
I. Mice 
Male, 6-to-12 week old wild-type C3H/HeN mice were purchased from Charles 
River Laboratories (Wilmington, MA). Male and female, 6-to-12-week old, IL-10- 
deficient or wild-type C57BL/6 mice were obtained from J.-A. Lyons (University of 
Wisconsin-Milwaukee). All mice were housed in micro-isolator cages in a 
humidity- and temperature-controlled environment under a 12-hour light/dark 
schedule at the University of Wisconsin-Milwaukee animal facility. Food and 
water were provided ad libitum. Experimental protocols were reviewed and 
approved by the University of Wisconsin-Milwaukee Institutional Animal Care and 
Use Committee.  
 
II. Vaccination of Mice 
Borrelia bissettii (formerly B. burgdorferi strain C-1-11) organisms were provided 
by S. M. Callister (Gundersen Lutheran Medical Center, La Crosse, WI). These 
organisms were heat-inactivated by incubating for 30 minutes in a 56°C water 
bath. Successful inactivation was determined by observing a lack of motility 
under dark-field microscopy. In addition, these organisms failed to grow in 
Barbour-Stoenner-Kelly (BSK) medium at 34°C for 7 d ays. The heat-inactivated 
organisms were then washed 4 times by centrifuging with phosphate-buffered 
saline (PBS; 7000g, 10 minutes), followed by resuspension in PBS. The heat-
inactivated organisms were then combined with 1% aluminum hydroxide to 
create a 4 x 106 organisms/mL vaccine preparation. Mice were injected 
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subcutaneously in each inguinal region with 0.25 mL vaccine preparation while 
under anesthesia with isoflurane in a nose-and-mouth cup.   
 
III. Infection of Mice 
B. burgdorferi strain 297 organisms were provided by S. M. Callister (Gundersen 
Lutheran Medical Center, La Crosse, WI). Organisms were grown at 34°C for 3-6 
days in BSK medium. Twenty-one days after vaccination, mice were injected 
subcutaneously in each hind paw with 106 viable B. burgdorferi strain 297 
organisms in 0.05 mL BSK medium while anesthetized with isoflurane in a nose-
and-mouth cup. Control groups were created by sham-infecting vaccinated mice 
(injecting with BSK medium alone) or injecting vaccinated mice with heat-killed B. 
burgdorferi strain 297 organisms in BSK medium. In other studies, non-
vaccinated mice were infected with B. burgdorferi strain 297 in a similar manner. 
Control groups were created by sham-infecting non-vaccinated mice (injecting 
with BSK medium alone). 
 
IV. Antibody Treatment 
Monoclonal antibody specific for mouse IFN-γ (clone 37895) was purchased from 
R & D Systems (Minneapolis, MN). The antibodies were resuspended in PBS to 
achieve a concentration of 50 µg/mL. One hour after infection, mice were injected 
with 2.5 µg (0.05 mL) anti-IFN-γ antibody subcutaneously in each hind paw while 
anesthetized with isoflurane in a nose-and-mouth cup. Mice were then injected 
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daily for 7 days. Control mice were injected similarly with either an isotype control 
antibody in PBS or PBS alone.   
 
V. Assessment of Inflammation 
Hind paw swelling was assessed by measuring the width and thickness of the 
tibiortarsal joints using a digital caliper (Marathon). These measurements were 
averaged to provide a measure for each paw. Hind paw swelling was measured 
immediately prior to infection with B. burgdorferi (or injection with BSK medium) 
and then every other day thereafter. Measurements were obtained prior to 
injection of antibodies, isotype control antibodies, or PBS.  
 
VI. Cell Culture 
On days 8 or 10 after infection (the days of peak hind paw swelling), inguinal and 
popliteal lymph nodes and/or spleens were harvested from B. bissettii-vaccinated 
mice injected with live B. burgdorferi 297, heat-killed B. burgdorferi 297, or BSK 
medium. Single-cell suspensions were generated by passing cells through a 
nylon mesh screen into cold Dulbecco’s Modified Eagle’s Medium or Roswell 
Park Memorial Institute 1640 medium. 1 x 106 cells were incubated at 37°C in 5% 
CO2 with or without 1 x 105 viable B. burgdorferi strain 297 organisms and with or 
without 5 µg (5µL) anti-mouse CD4 antibodies (clone GK1.5; eBioscience, San 
Diego, CA). Supernatants were collected after 6 and 24 hours of incubation. 
Controls consisted of cells incubated without antibodies or organisms. 
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VII. ELISA 
Blood was collected by intracardiac puncture on days 8, 10, or 12 after infection. 
Levels of serum IL-17 and IFN-γ were determined using IL-17A and IFN-γ ELISA 
Ready-Set-Go! Kits (eBioscience, San Diego, CA) according to the 
manufacturer’s directions. Cytokine levels were also assessed from cell culture 
supernatants. The plates were read at 450nm and values were expressed as 
optical densities. Standard curves were created and used to calculate pg 
cytokine/mL for each sample. Cytokine levels not detectable by ELISA were 
given a value of 0.00 pg/mL for statistical purposes.   
 
VIII. Borreliacidal Antibody Assay 
Sera or cell culture supernatants were used to determine titers of borreliacidal 
antibodies. Samples of serum or supernatant were pooled within a group. Each 
pooled sample was diluted 1:20 in PBS, passed through a 0.2 µm filter, and then 
further diluted serially, 1:40 to 1:10,240, with PBS. The diluted specimens were 
heated at 56°C for 30 minutes to inactivate complemen t and then cooled to 35°C. 
The complement-inactivated specimens were incubated with 104 viable B. 
burgdorferi 297 organisms and 20 µL of sterile guinea pig complement (Sigma-
Aldrich; St. Louis, MO) in PBS for 24 hours. The presence of viable microbes 
was then observed in 20 fields using dark-field microscopy. The titer of 
borreliacidal antibody was considered the reciprocal of the final dilution in which 
motile B. burgdorferi was observed. Controls contained B. burgdorferi 297 and 
complement (without sample), B. burgdorferi 297 and PBS (without complement 
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or sample), and B. burgdorferi 297 and PBS added to a sample (without 
complement). A four-fold increase in borreliacidal antibody titer was considered 
significant.  
 
IX. Statistics 
The results of some studies were expressed as mean ± standard error of the 
mean (SEM) and analyzed using a two-tailed Student's t-Test to determine the 
level of significance. Other data were analyzed by one-way analysis of variance 
(ANOVA) followed by the Tukey-Kramer post-hoc test. All P-values were 
calculated with the alpha level set at 0.05 prior to initiation of experiments.   
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CHAPTER 3: RESULTS 
I. Specific Aim 1: Establish CD4+ cells as a source of IL-17 following 
infection with B. burgdorferi.   
1. Effects of anti-IFN-γ antibody administration on hind paw swelling 
This study was performed to assess the requirement of IFN-γ for inflammation 
following B. burgdorferi infection. Non-vaccinated, B. burgdorferi-infected C3H 
mice were injected with anti-IFN-γ or isotype-control antibodies, and the swelling 
of the hind paws was measured throughout infection. Control mice were injected 
with BSK medium, followed by injections with PBS. The B. burgdorferi-infected 
mice administered isotype-control antibodies developed greater swelling of the 
hind paws than non-infected control mice. Swelling was observed on day 2 after 
infection, peaked at day 9, and gradually subsided (Figure 1). This swelling 
remained greater than that observed in control mice until day 17 after infection. In 
addition, B. burgdorferi-infected mice injected with anti-IFN-γ antibodies exhibited 
a pattern of hind paw swelling similar to that of infected mice injected with isotype 
control antibodies. An additional group of B. burgdorferi-infected mice injected 
daily with PBS alone developed swelling not significantly different than that of 
infected mice injected with isotype control antibodies (data not shown). 
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2. Serum levels of IL-17 following treatment with anti-IFN-γ antibodies 
Th1 and Th17 cells are known to act antagonistically through IFN-γ and IL-17, 
respectively. To determine the effect of anti-IFN-γ antibody treatment on IL-17 
production, sera were collected from B. burgdorferi 297-infected C3H mice 
treated with anti-IFN-γ or isotype control antibodies on days 7, 12, 21, and 47 
after infection. The amounts of serum IL-17 in these mice were then assessed by 
ELISA. The levels of serum IL-17 in B. burgdorferi-infected mice injected with 
isotype control antibodies increased gradually from day 7 (15.5 pg/mL) to day 12 
(28.1 pg/mL) to day 21 (47.5 pg/mL). By contrast, the levels of serum IL-17 in 
infected mice treated with anti-IFN-γ antibodies increased rapidly from day 7 
(19.9 pg/mL) to day 12 (44.9 pg/mL), and then decreased by day 21 (35.6 
pg/mL). Infected, anti-IFN-γ-antibody-treated mice had a significantly greater 
Figure 1. Administration of anti-IFN-γ antibody does not affect paw swelling in 
B. burgdorferi-infected C3H mice. Mice were infected with B. burgdorferi 297 
and treated with anti-IFN-γ antibody (n=10) or an isotype control antibody (n=10)
for 7 days.  Non-infected control mice (n=10) were treated with PBS. Error bars 
indicate the SEM. 
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amount of serum IL-17 than infected, non-treated mice at day 12 after infection 
(P=0.0006; Figure 2). The amount of serum IL-17 in non-infected controls 
gradually decreased following injections of BSK and PBS, and no significant 
amounts of serum IL-17 were detected in any group at day 47 after infection 
(data not shown). 
 
 
 3. Role of sustained infection on production of IL-17 
The Borrelia-vaccination and -infection model of Lyme arthritis was used to      
investigate whether live B. burgdorferi infection, as opposed to a non-viable 
infection, is required for an IL-17 response associated with increased hind-paw 
swelling. C3H mice were vaccinated with B. bissettii and later injected with viable 
B. burgdorferi 297 organisms, heat-killed B. burgdorferi 297 organisms, or BSK 
medium. The swelling of their hind paws was measured. Vaccinated mice 
infected with live B. burgdorferi developed significantly greater paw swelling than 
Figure 2. Concentrations of IL-17 in serum of non-infected C3H mice (n=5) and 
C3H mice infected with B. burgdorferi 297, with (n=5) or without (n=5) 
administration of anti-IFN-γ antibodies, at day 12 after infection. * denotes a 
significant difference (P<0.05). Error bars indicate the SEM. 
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mice injected with dead B. burgdorferi or medium consistently by day 8 after 
infection (p=0.003; Figure 3). All mice were sacrificed at day 10 after these 
injections, near the presumed peak swelling time after infection. 
 
 
 
 
From these mice, cell culture supernatants of unseparated inguinal lymph nodes 
cells cultured with live B. burgdorferi 297 organisms were measured for IL-17 
production. Upon in vitro stimulation with viable B. burgdorferi 297, cells 
harvested from Borrelia-vaccinated- and -infected mice produced less, but not 
statistically different, levels of IL-17 than stimulated cells obtained from Borrelia-
vaccinated mice injected with non-viable spirochetes or BSK medium (Figure 4). 
Figure 3. Hind paw swelling of Borrelia-vaccinated C3H mice injected with live
(n=16) or heat-killed (n=12) B. burgdorferi 297 (Bb). A control group consisted of 
vaccinated mice that were not infected (n=8). * denotes a significant (P<0.05) 
difference in paw swelling. Error bars indicate SEM. 
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4. Assessment of IL-17 production in different models of Lyme arthritis 
Both the Borrelia-infection and Borrelia-vaccination and -infection models of 
Lyme arthritis were used to determine the relative abundance of IL-17 produced 
by spleen cells after infection with B. burgdorferi. To characterize these 
differences, the amounts of IL-17 produced by cells from wild-type C57BL/6 mice 
obtained at the peak of swelling in both models were determined. Spleen cells 
were collected at day 8 after infection and then incubated with B. burgdorferi 297 
for 6 or 24 hours. 
 
Cells obtained from naïve, wild-type mice produced non-detectable levels of IL-
17 when cultured with B. burgdorferi 297 for 6 hours (Figure 5). Production of IL-
17 by these cells increased after 24 hours, but the increase did not reach 
Figure 4. Concentrations of IL-17 from culture supernatants of lymph node cells 
from Borrelia-vaccinated C3H mice injected with live (n=3) or heat-killed (n=4) B. 
burgdorferi 297 (Bb) or BSK medium (n=2). Cells were obtained at day 10 after 
infection and restimulated with B. burgdorferi 297.  Error bars indicate SEM. 
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statistical significance (P=0.08). Similarly, cells from B. burgdorferi-infected mice 
that were restimulated with the spirochete for 6 hours produced low levels of IL-
17. No difference in IL-17 production was detected after 24 hours (Figure 5). 
When comparing IL-17 production between cells from naïve and infected mice 
after in vitro stimulation, there were no significant differences observed at either 
time point. 
 
Cells obtained from Borrelia-vaccinated, wild-type mice, whether or not the mice 
were infected, produced no detectable IL-17 when cultured with B. burgdorferi 
297 for 6 hours (Figure 5). However, upon in vitro stimulation with viable B. 
burgdorferi 297, cells from vaccinated, non-infected mice produced significantly 
more IL-17 after 24 hours (P=0.008; Figure 5). The amount of IL-17 produced 
from cells of naïve mice, non-vaccinated but infected mice, and vaccinated-and-
infected mice after 24-hour restimulation was significantly lower than the amount 
of IL-17 produced from cells of vaccinated, non-infected mice (P=0.008).  
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5. Assessment of Borrelia-induced IL-17 production in models of Lyme arthritis in 
IL-10-deficient mice 
The role of the anti-inflammatory cytokine IL-10 on the production of IL-17 in the 
Borrelia-infection and Borrelia-vaccination and -infection models of Lyme arthritis 
was characterized. Spleen cells were collected from IL-10-deficient mice of both 
models at day 8 after the day of infection and then incubated with B. burgdorferi 
297 for 6 or 24 hours. 
 
Spleen cells from naïve, IL-10 knock-out (KO) mice produced low levels of IL-17 
following incubation with B. burgdorferi 297 for 6 hours (Figure 6). No significant 
Figure 5. Concentrations of IL-17 from culture supernatants of spleen cells 
obtained from naïve (n=7), Borrelia-infected (n=8), Borrelia-vaccinated (n=6), 
and Borrelia-vaccinated and –infected (n=6) wild-type (WT) C57BL/6 mice. 
Cells were obtained at peak swelling (8 days after the time of infection) and 
then stimulated with B. burgdorferi in vitro for 6 or 24 hours.  * denotes a 
significant difference (P<0.05). ND, not detected. Error bars indicate SEM. 
 
28 
 
increase was observed after 24 hours of incubation. By contrast, IL-17 production 
by spleen cells of Borrelia-infected IL-10 KO mice increased significantly, by 
1300% (P=0.005), between 6 and 24 hours of restimulation with B. burgdorferi 
297 (Figure 6). In addition, stimulated spleen cells from infected mice produced 
greater amounts of IL-17 than stimulated cells from naïve mice at each time 
point. The increases at both time points, however, were not significant. 
 
Cells obtained from Borrelia-vaccinated, non-infected IL-10 KO mice produced 
low amounts of IL-17 after 6 hours of stimulation with B. burgdorferi 297 (Figure 
6). A highly significant increase of 3600% (P=0.002) in IL-17 production was    
observed from these cells after 24 hours of incubation. .However, no differences 
in IL-17 production were observed between these groups after 24 hours of 
incubation with the spirochete. 
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6. Effect of IL-10 deficiency on IL-17 production in models of Lyme arthritis 
Using the data described above, the effect of IL-10 deficiency on IL-17 
production during the peak phase of swelling following B. burgdorferi infection 
was assessed. In both models of infection (non-vaccinated but Borrelia-infected; 
Borrelia-vaccinated and -infected) and both control groups (non-vaccinated and 
non-infected [naïve]; Borrelia-vaccinated but non-infected), spleen cells of IL-10 
KO mice produced more IL-17 when exposed to B. burgdorferi 297 in vitro than 
cells of wild-type mice. Naïve IL-10 KO cells displayed higher levels of IL-17 after 
6 and 24 hours of incubation (Figure 7), with significantly higher levels detected 
after the 6-hour incubation (P=0.05). Similar results were observed from the cells 
of Borrelia-infected IL-10 KO mice, with significant increases of IL-17 production 
Figure 6. Concentrations of IL-17 from culture supernatants of spleen cells 
obtained from naïve (n=6), Borrelia-infected (n=8), Borrelia-vaccinated
(n=10), and Borrelia-vaccinated and –infected (n=10) IL-10 knock-out (KO) 
C57BL/6 mice. Cells were obtained at peak swelling (8 days after the time of 
infection) and then stimulated with B. burgdorferi in vitro for 6 or 24 hours.  * 
denotes a significant difference (P<0.05). Error bars indicate SEM. 
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at 6 hours (2400%, P=0.0003) and at 24 hours (10,700%, P=0.02) compared to 
cells of infected wild-type mice (Figure 7).  
 
 
 
 
Similarly, significantly greater levels of IL-17 were produced by stimulated spleen 
cells of Borrelia-vaccinated, non-infected IL-10 KO mice after 6 hours (P=0.001) 
and 24 hours (770%, P=0.02) of incubation compared to stimulated cells of wild-
type mice (Figure 8). Also, stimulated spleen cells from Borrelia-vaccinated and -
infected IL-10 KO mice produced significantly more IL-17 after 6 hours 
(P=0.0005) and 24 hours (3300%, P=0.01) of incubation compared to cells from 
wild-type mice. 
Figure 7. Concentrations of IL-17 from culture supernatants of spleen cells 
obtained from wild-type (WT) and IL-10-deficient (KO), naïve (n=7) and 
Borrelia-infected (n=8) C57BL/6 mice. Cells were obtained at peak swelling 
(day 8 after the time of infection) and were stimulated with B. burgdorferi in 
vitro for 6 or 24 hours. * denotes a significant difference (P<0.05). ND, not 
detected. Error bars indicate SEM. 
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7. Anti-CD4 antibody modulation of IL-17 in models of Lyme arthritis 
Here, the contribution of CD4-expressing cells to the production of IL-17 in the 
Borrelia-infection and Borrelia-vaccination and -infection models of Lyme arthritis 
was assessed. Spleen cells were harvested at the peak of swelling from wild-
type and IL-10-deficient mice and incubated for 6 and 24 hours with B. 
burgdorferi, with or without anti-CD4 antibodies. Data from cells incubated 
without anti-CD4 antibody have been shown previously (Figures 5-8). 
 
No differences in IL-17 production due to anti-CD4 antibodies were observed 
among stimulated cells from naïve, wild-type mice at either 6 or 24 hours of     
incubation (Figure 9). By contrast, after 24 hours of incubation with anti-CD4    
Figure 8. Concentrations of IL-17 from culture supernatants of spleen cells 
obtained from wild-type (WT) and IL-10-deficient (KO), Borrelia-vaccinated (n=8)
and Borrelia-vaccinated and –infected (n=8) C57BL/6 mice. Cells were obtained at 
peak swelling (day 8 after the time of infection) and were stimulated with B. 
burgdorferi in vitro for 6 or 24 hours. * denotes a significant difference (P<0.05). 
ND, not detected. Error bars indicate SEM. 
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antibodies, stimulated cells from non-vaccinated, B. burgdorferi-infected wild-type 
mice produced 86% less IL-17 than stimulated cells not exposed to antibodies 
(Figure 9); this difference was significant (P=0.03). These results were not 
observed after 6 hours of incubation. Also, after 24 hours of incubation with anti-
CD4 antibodies, stimulated spleen cells from Borrelia-vaccinated, non-infected 
wild type mice produced 44% less IL-17 than cells not incubated with antibodies. 
However, this decrease was not significant (P=0.10; Figure 9). No changes in IL-
17 production were detected following anti-CD4 antibody treatment of stimulated 
cells obtained from Borrelia-vaccinated and -infected wild-type mice at either time 
point. 
 
 
 
 
 
Figure 9. Concentrations of IL-17 from culture supernatants of spleen cells from 
naïve (n=6), Borrelia-infected (n=8), Borrelia-vaccinated (n=6), and Borrelia-
vaccinated and –infected (n=6) wild-type (WT) C57BL/6 mice. Cells were 
obtained at peak swelling (day 8 after the time of infection) and then stimulated 
with B. burgdorferi 297 (Bb), with or without anti-CD4 antibody (αCD4). * denotes 
a significant difference (P<0.05). ND, not detected. Error bars indicate SEM. 
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The effects of anti-CD4 antibodies on IL-17 production were also assessed 
among stimulated spleen cells obtained from IL-10 KO mice. No differences in IL-
17 production due to anti-CD4 antibodies were observed among stimulated cells 
from naïve IL-10 KO mice, Borrelia-infected IL-10 KO mice, or Borrelia-
vaccinated, non-infected IL-10 KO mice after either 6 or 24 hours of    incubation 
(Figure 10). By contrast, a statistically significant decrease (56%, P=0.006) in IL-
17 production was observed among stimulated, anti-CD4 antibody-treated cells 
from Borrelia-vaccinated and -infected IL-10 KO mice at 6 hours of incubation. 
However, no differences in IL-17 production were exhibited at 24 hours of 
incubation. 
 
 
 
 
 
 
Figure 10. Concentrations of IL-17 from culture supernatants of spleen cells 
from naïve (n=6), Borrelia-infected (n=8), Borrelia-vaccinated (n=10), and 
Borrelia-vaccinated and –infected (n=10) IL-10 deficient (KO) C57BL/6 mice. 
Cells were obtained at peak swelling (day 8 after the time of infection) and then 
stimulated with B. burgdorferi 297 (Bb), with or without anti-CD4 antibody 
(αCD4). * denotes a significant difference (P<0.05). Error bars indicate SEM. 
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II. Specific Aim 2: Establish a relationship between IL-17 levels and 
borreliacidal antibody production. 
1. Borreliacidal antibody titers following sustained infection with B. burgdorferi 
The data presented previously indicate that stimulation of lymph node cells from 
Borrelia-vaccinated C3H mice infected with live B. burgdorferi 297 resulted in 
less IL-17 production than stimulation of cells from Borrelia-vaccinated mice 
injected with non-viable spirochetes. Therefore, borreliacidal antibody titers were 
assessed from cell culture supernatants in order to examine increased microbe 
killing in vitro as a possible reason for these unexpected results. Lymph node 
cells from Borrelia-vaccinated, non-infected mice, incubated with B. burgdorferi 
297 in vitro, produced a borreliacidal antibody titer of 640 against B. burgdorferi 
297 (Figure 11). By contrast, cells from Borrelia-vaccinated mice injected with 
viable or heat-killed B. burgdorferi 297 both produced significantly higher titers of 
borreliacidal antibody, which exceeded the detection ability of the assay (≥ 
10,240). 
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2. Effect of IL-10 on borreliacidal antibody titers in models of Lyme arthritis 
Hind paws of IL-10 KO, C57BL/6 mice developed greater swelling after infection 
with B. burgdorferi than their wild-type counterparts (data not shown). The cells 
of these mice also had a greater IL-17-producing capacity following in vitro 
exposure to the spirochete than wild-type cells (Figures 5-8). Borreliacidal 
antibody titers were measured from the sera of these mice at the peak of paw 
swelling to examine the effect of IL-10 on a possible mechanism responsible for 
clearing infection. As expected, naïve, wild-type mice possessed a low level of 
borreliacidal antibody against B. burgdorferi 297 (titer, 10; Figure 12). Absence of 
IL-10 caused a significant (8-fold) increase in titers. However, these titers were 
still very low. Absence of IL-10 slightly, but insignificantly, increased the 
borreliacidal antibody titers in non-vaccinated, B. burgdorferi 297-infected mice 
(titer, 40) compared to wild-type mice (titer, 20). Lack of IL-10 in Borrelia-
Figure 11. Borreliacidal antibody titers from culture supernatants of lymph 
node cells from Borrelia-vaccinated C3H mice injected with live (n=8) or 
heat-killed (n=6) B. burgdorferi 297 or BSK medium (n=4). Cells were 
obtained at the peak of swelling (day 10 after the time of injections) and 
stimulated with B. burgdorferi 297 in vitro for 24 hours.  * denotes a 
significantly greater (4-fold) titer than that of cells from non-infected mice. 
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vaccinated, non-infected mice significantly increased the borreliacidal antibody 
titers (titer, ≥10,240) against B. burgdorferi 297 compared to wild-type mice (titer, 
640). The titers of borreliacidal antibody in Borrelia-vaccinated and -infected 
mice, regardless of strain, exceeded the levels of detection in the assay 
(≥10,240). 
 
Figure 12. Borreliacidal antibody titers obtained from sera of naïve (n=4), Borrelia-
infected (n=4), Borrelia-vaccinated (n=4), and Borrelia-vaccinated and -infected 
(n=4) wild-type (WT) and IL-10-deficient (KO) C57BL/6 mice at the peak of hind paw 
swelling (day 8 after the time of infection). * denotes a significantly greater (4-fold) 
titer than wild-type counterparts. 
 
37 
 
CHAPTER 4: DISCUSSION 
 
This thesis contributes to knowledge of how IL-17 is involved in the inflammatory 
response to B. burgdorferi. IL-17 is a pro-inflammatory cytokine that is produced 
in response to B. burgdorferi infection (35) and is associated with various forms 
of arthritis (37-40). Recent studies have also characterized the role of IL-17 and 
related cytokines in the development of Lyme arthritis, leading to the hypothesis 
that Th17 cells are a potential contributor to disease (45). In addition, since IL-17 
is produced by other cell types in addition to Th17 cells (21, 69), the contribution 
of potential Th17 cells to the production of IL-17 in response to B. burgdorferi is 
unknown. Also, whether IL-17 is associated with the protective borreliacidal 
antibody response has not been fully examined. The objective of this thesis was 
to elucidate the contributions of IL-17-producing CD4+ cells in the development 
of B. burgdorferi-induced arthritis and IL-17 in the stimulation of the borreliacidal 
antibody response. The following specific aims were pursued to test this 
hypothesis: (1) Establish CD4+ cells as a source of IL-17 following infection with 
B. burgdorferi; (2) Establish a relationship between IL-17 levels and borreliacidal 
antibody production.   
 
I. Specific Aim 1: Establish CD4+ cells as a source of IL-17 following 
infection with B. burgdorferi. 
Th17 and Th1 cells have been shown to have an antagonistic relationship though 
the effects of IL-17 and IFN-γ, respectively (50). In order to explore the role of IL-
17 in a reduced Th1 environment during Lyme arthritis, mice were infected with 
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B. burgdorferi 297 and then injected with anti-IFN-γ antibody. These mice 
developed similar degrees of paw swelling than B. burgdorferi-infected, isotype 
antibody-treated controls (Figure 1). However, a greater degree of peak paw 
swelling was observed, although this difference was not statistically significant 
(Figure 1). Additionally, the serum of Borrelia-infected mice treated with anti-IFN-
γ antibody contained greater levels of IL-17 than non-treated, infected controls 
(Figure 2). These results are consistent with previous findings in which mice 
genetically deficient in IFN-γ, its receptor, or its signaling pathway can develop 
Lyme arthritis (29, 30, 31), which demonstrates that IFN-γ is not the sole cytokine 
responsible for the development of pathology. Furthermore, these findings 
provide additional support for the antagonistic relationship between Th1 and 
Th17 cells (50). They also support findings in Borrelia-infected mice that 
demonstrated an increase in IFN-γ following treatment with anti-IL-17 antibodies 
(70). The results presented here are consistent with these data by displaying this 
inverse relationship, since anti-IFN-γ antibody treatment led to an increase in IL-
17 production (Figure 2). Non-infected control mice also produced low levels of 
IL-17 (Figure 2). This is most likely due to the daily injections of PBS that these 
mice received. The repeated trauma would likely produce a mild inflammatory 
response, resulting in low levels of IL-17.   
 
These data also fit with research establishing IL-17 as a contributor to Lyme 
arthritis using the Borrelia-vaccination and -infection model of disease, which 
reflects later-stage arthritis in humans through its significant involvement of CD4+ 
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T cells (32, 33). Christopherson, et al. showed that Borrelia-vaccinated and -
infected C57BL/6 mice lacking IFN-γ (i.e., the Th1 response) developed severe, 
destructive arthritis (30), pointing to the involvement of other inflammatory 
mechanisms. IL-17, which recently had been shown to be produced by helper T 
cells in response to B. burgdorferi (35), was investigated as a possible cause of 
Lyme arthritis. Treatment of Borrelia-vaccinated and -infected IFN-γ KO mice 
with anti-IL-17 antibodies at the time of infection for 11 days (43) or 7 days (49) 
prevented the development of arthritis. In addition, treatment of wild-type 
C57BL/6, Borrelia-vaccinated and -infected mice with anti-IL-17 antibodies 
reduced the severity of pathology (45), although not to the level observed in 
treated IFN-γ KO mice (43, 49). This shows that IFN-γ may be an important 
regulator of IL-17, possibly from T cells, in Lyme arthritis. 
 
Following these earlier findings in the context of B. burgdorferi infection, Park, et 
al. (34) described the existence of a unique subpopulation of IL-17-producing 
CD4+ T cells (Th17 cells). Bettelli, et al. (44) then showed that the development 
of these cells from naïve T cells in vitro required a combination of IL-6 and TGF-
β. Veldhoen, et al. extended this observation to show that TGF-β, in the 
presence of inflammatory mediators (IL-1β, IL-6, TNF-α), leads to Th17 
differentiation (71). Also, survival of Th17 cells was shown to require stimulation 
with IL-23 (44). IL-23 is also required for full differentiation of Th17 cells (72) and 
is also induced by B. burgdorferi stimulation (46). Using the Borrelia-vaccination 
and -infection model in wild-type C57BL/6 mice, it was shown that neutralization 
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of IL-23 prevented arthritis and was required for IL-17 production in vitro (47). In 
addition, injection of infected mice with a combination of anti-IL-6 and anti-TFG-β 
antibodies reduced arthritic pathology (45). Codolo, et al. (48) provided direct 
evidence that Th17 cells are found in the joints of human Lyme arthritis patients. 
Specifically, neutrophil activating protein A of B. burgdorferi causes the release of 
IL-6, IL-1β, TGF-β, and IL-23 from various innate cells, which work together to 
stimulate synovial T cells to produce IL-17 (48). The findings presented here 
provide additional support that T cells are a possible source of IL-17 during the 
peak arthritic stage after infection with B. burgdorferi. However, direct evidence 
of a role for Th17 has not yet been shown. 
 
Conflicting evidence exists for a role for Th17 cells in Lyme arthritis. Th17 cells 
were also found in the synovial fluid and tissues of humans with disease by 
Shen, et al. (28). However, they found the Th17 population to only comprise 
approximately 10% of the CD4+ T cell population in most patients (28). They did 
not examine the arthritic potential of these cells, but concluded that they may not 
contribute to disease. Consistent with this study, Oosting, et al. (73) showed that 
some humans possess a polymorphism of the IL-23 receptor that causes 
defective binding of the cytokine. Humans with this polymorphism who are also 
infected with B. burgdorferi produce less IL-17 than those without the 
polymorphism, but the severity of their arthritis does not differ (73). However, 
these data were collected with relatively low sample sizes in humans (28, 73). 
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The natural variation in humans, coupled with these low sample sizes, prevents 
absolute conclusions from being made. 
 
In order to determine whether established Borrelia infection was required to 
stimulate this inflammatory cascade, vaccinated mice were challenged with either 
live or heat-killed B. burgdorferi 297. Borrelia-vaccinated mice infected with live 
organisms developed significantly greater swelling at peak disease (Figure 3). 
Unexpectedly, unseparated lymph node cells from these mice, following 
restimulation with B. burgdorferi 297 (the microbe of infection), produced less   
IL-17 than stimulated cells obtained from vaccinated mice injected with heat-
killed organisms (Figure 4). These surprising results may have occurred due to 
differences in the immune response to primary versus secondary exposure to live 
organisms. The first exposure of cells from Borrelia-vaccinated mice injected with 
heat-killed spirochetes to live B. burgdorferi 297 occurred in culture. By contrast, 
lymph node cells from Borrelia-vaccinated, B. burgdorferi 297-infected mice had 
already been exposed to the live bacteria and were encountering it for the 
second time while in culture. Since secondary, ex vivo exposure decreased IL-17 
production, it was thought that this restimulation may have caused a robust 
borreliacidal antibody response from B cells present in the unseparated lymph 
node cultures (examined in Specific Aim 2 below). Rapid stimulation of 
borreliacidal antibodies may have cause the killing of the bacteria in culture, 
resulting in a reduced antigenic stimulus and less IL-17 production. 
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By contrast, Ganapamo et al. (74) investigated the cytokine response to B. 
burgdorferi strain JD1 infection by simulating lymph node cells of infected mice 
with the same isolate in vitro. However, these mice were not vaccinated before 
infection, unlike the mice used in these studies. It was previously shown that cells 
from B. bissettii-vaccinated, non-infected mice produced cytokines associated 
with Th17 cells when exposed to B. burgdorferi 297 for the first time in vitro (47, 
75). These studies, with the data presented here, show that a secondary 
exposure to a live B. burgdorferi strain in vitro, using the Borrelia-vaccination and 
-infection model, likely do not yield cytokine results that reflect primary infection. 
However, this secondary exposure may allow for examination of the borreliacidal 
antibody response, given that B cells in these unseparated cell cultures may be 
highly activated. 
 
To further explore the role of adaptive immune sources of IL-17, we examined 
the effects of the Borrelia-infection and Borrelia-vaccination and -infection models 
on the production of the cytokine. Researchers typically use the Borrelia-infection 
model of Lyme arthritis, in which C3H, “arthritis-susceptible” mice, are infected 
with Borreliae (56). This model, however, favors the events of innate immunity, 
which may not appropriately mimic the adaptive immune response involvement 
seen in humans with later-stage disease (70). The Borrelia-vaccination and -
infection model addresses this issue by priming and activating T cells, resulting in 
a stronger adaptive immune response (70). Spleen cells harvested from mice at 
peak swelling were used to evaluate IL-17 production in vitro. Cells from naïve 
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and Borrelia-infected wild-type mice produced low levels of IL-17 upon incubation 
with live B. burgdorferi 297, with little change occurring between the 6 and 24 
hour incubations (Figure 5). These results were expected, considering that the 
Borrelia-infection model may not fully reflect the involvement of IL-17 following B. 
burgdorferi infection (70). By contrast, cells from Borrelia-vaccinated, non-
infected mice produced significantly higher levels of IL-17 after 24 hours in 
culture (Figure 5). These results are consistent with the rationale behind the use 
of the Borrelia-vaccination and -infection model, which primes T cells at 
vaccination and involves a greater adaptive immune response, especially the 
adaptive IL-17 response, upon infection with live organisms (70). Cells from 
Borrelia-vaccinated and -infected mice also produced higher, but not significantly 
greater, levels of IL-17 at the 24 hour incubation time point (Figure 5). These 
levels, however, were lower than those seen in the stimulated cells from Borrelia-
vaccinated, non-infected mice. This again points to the possible differences in the 
development of borreliacidal antibodies occurring in primary versus secondary 
exposure.  Regardless, cells from Borrelia-vaccinated, but non-infected mice had 
greater levels of IL-17 than cells from naïve, non-vaccinated, but B. burgdorferi-
infected, and Borrelia-vaccinated and -infected mice, supporting the hypothesis 
that the Borrelia-vaccination and -infection model of disease better reflects the 
involvement of IL-17 in the response to the spirochete (70). 
 
Additionally, IL-10-deficient mice on a C57BL/6 background have been proposed 
as another model of Lyme arthritis (76). This is due, in part, to the involvement of 
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T cells that lead to a sustained IFN-γ response, which reflects the persistent 
arthritis that occurs in humans (76). Wild-type C57BL/6 mice are typically 
resistant to arthritis and, generally, produce more IL-10 in response to Borrelia 
exposure (29). Conversely, susceptibility to developing Lyme arthritis has been 
linked to an early production of IL-10 after infection with B. burgdorferi, which 
regulates the effects of IFN-γ (74), macrophages (77), and macrophage signaling 
pathways (78) in the response to infection. IL-10 also has been shown to inhibit 
the production of IL-17 by Th17 cells (79). However, the effect of IL-10 on IL-17 
production in Lyme arthritis has not been investigated. 
 
Here, the production of IL-17 in the different models was compared. Cells from 
non-vaccinated, Borrelia-infected IL-10 KO mice produced highly increased 
levels of IL-17 between 6 and 24 hours of in vitro stimulation (Figure 6), a change 
that was not seen in wild-type counterparts (Figure 5). These IL-10 KO cells 
produced significantly more IL-17 than wild-type cells at both time points (Figure 
7). Similarly, stimulated cells from Borrelia-vaccinated, non-infected IL-10 KO 
mice produced amounts of IL-17 which were significantly greater than wild-type 
counterparts at both time points (Figure 8).  
 
In general, stimulated spleen cells from all IL-10 KO groups developed greater 
levels of IL-17 (Figure 8) and hind paw swelling (data not shown) than their wild-
type counterparts. As expected, this indicates that the presence of IL-10, an anti-
inflammatory cytokine, inhibits the production of IL-17. In support of these 
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findings, IL-10 directly inhibits the activity of Th17 cells and T cells that produce 
both IL-17 and IFN-γ in a model of colitis (79). In terms of Lyme arthritis, 
specifically, these findings are also consistent with those of others. B. 
burgdorferi-infected IL-10 KO mice retain more spirochetes in their tissues (80) 
and develop greater paw swelling (76) than infected wild-type mice. This lack of 
IL-10 was associated with increased levels of IFN-γ, and neutralization of this 
IFN-γ reduced inflammation (76). These researchers did not examine the effects 
of IL-10 deficiency on IL-17, however. Here, we show that IL-10 deficiency 
increases levels of IL-17 following infection with B. burgdorferi, and future studies 
will assess the contribution of IL-17 to arthritis in these mice. The findings here, 
which show an additional effect of IL-10 on inflammation caused by a known 
helper T cell cytokine, support the hypothesis that IL-17 formed in response to B. 
burgdorferi infection may be derived from CD4+ T cells.  
 
To obtain additional support for this, CD4 was blocked in in vitro cultures of 
stimulated spleen cells obtained at peak swelling in different models of Lyme 
arthritis. This was done to assess the contribution of IL-17-secreting CD4+ cells 
(likely Th17 cells) in the different models of disease. Significant decreases in the 
production of IL-17 were induced following administration of an anti-CD4 
antibody in stimulated cells from Borrelia-infected, wild-type mice (Figure 9). This 
exposure to live organisms likely resulted in an increased CD4+ T cell (potentially 
Th17 cell) response that was sensitive to the effects of the antibody. In addition, 
cells from vaccinated, but not infected, wild-type mice also trended toward a 
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decrease in IL-17 with exposure to anti-CD4 antibody, though this decrease was 
not statistically significant (Figure 9). A significant decrease in IL-17 following 
anti-CD4 antibody treatment was expected in this group, as the in vitro culture 
was these vaccinated cells’ primary exposure to live B. burgdorferi 297. As 
anticipated, significant IL-17 production was observed following this activation of 
vaccine-primed cells by a heterologous strain. Therefore, it may be that the 
amount of anti-CD4 antibody used was not sufficient to fully counter the level of 
Th17 cell activation and IL-17 production. Still, however, these data do point to 
the possible presence of Th17 cells stimulated by B. burgdorferi. In addition, 
other IL-17-producing cells may be induced by B. burgdorferi, since addition of 
anti-CD4 antibodies to cultures did not completely abrogate IL-17 production. 
 
Cells from Borrelia-vaccinated and -infected IL-10 KO mice did achieve a 
significant reduction in IL-17 in the presence of anti-CD4 antibody after 6 hours in 
culture (Figure 10). Considering that the lack of IL-10 in these cells could 
naturally skew towards a Th17 response after encountering antigen, these data 
are not surprising. In addition, since this decrease was not observed in cells from 
wild-type Borrelia-vaccinated and -infected mice (Figure 9), this may indicate just 
how powerful the effect of IL-10 is in inhibiting a Th17 response. However, no 
similar effect was observed in stimulated cells from non-vaccinated, Borrelia-
infected IL-10 KO mice or Borrelia-vaccinated, non-infected IL-10 KO mice. This 
may have resulted from the substantial amount of IL-17 produced by these cells, 
which may have been too great to counter with the amount of anti-CD4 antibody 
47 
 
used. A large amount of cell activation seems to have occurred in both of these 
groups upon in vitro stimulation for 24 hours. As previously stated, the increase 
in IL-17 production by cells from the Borrelia-vaccinated, non-infected IL-10 KO 
mice may be due to the primary exposure of these cells to the in vitro antigen, B. 
burgdorferi 297. However, non-vaccinated, Borrelia-infected IL-10 KO mice were 
challenged with B. burgdorferi 297, yet still contained cells that produced 
significant IL-17 during in vitro exposure to B. burgdorferi 297 (Figure 10). This 
may provide additional support that the Borrelia-infection model of Lyme arthritis 
does not reflect the in vivo IL-17 response well. However, this also points to the 
possibility that prior vaccination with B. bissettii may prime mice to robustly 
produce borreliacidal antibody against B. burgdorferi 297 following infection with 
this latter strain. In support of this, less IL-17 was observed in restimulated cells 
from Borrelia-vaccinated and -infected mice IL-10 KO mice than from infected IL-
10 KO mice that were not vaccinated (Figure 10). The effect of prior vaccination 
seems to affect the strength of the response to secondary antigen exposure. In 
any case, these data in IL-10 KO mice provide support that IL-17 may influence 
disease in Lyme arthritis. Also, Th17 cells may be a source of IL-17, though it is 
likely not the only source, as anti-CD4 antibody did not completely prevent 
production of IL-17. In future experiments, a dose-response experiment with anti-
CD4 antibody will be performed to account for the considerable IL-17 levels seen 
in these groups.   
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In summary, the working hypothesis for this aim was CD4+ cells are a significant 
source of IL-17 during B. burgdorferi-induced inflammation. These data provide 
support to this hypothesis. Known relationships between Th1 and Th17 cells, as 
well as between IL-10 and Th17 cells, were demonstrated following infection with 
B. burgdorferi. Importantly, these relationships were demonstrated at the peak of 
swelling in different Lyme arthritis models. In addition, CD4-expressing cells were 
shown to be involved in the production of IL-17 at the peak of swelling. One 
possible confounding factor was the unexpectedly low amount of IL-17 produced 
following secondary exposure to B. burgdorferi 297. However, this is explored in 
Specific Aim 2 and is discussed below.  
 
II. Specific Aim 2: Establish a relationship between IL-17 levels and         
borreliacidal antibody production. 
A potent antibody response is required for protection against B. burgdorferi 
infection and the ensuing inflammation. Th17 cells have been shown to exert 
effects on the ability of B cells to produce antibody (81). For example, Th17 cells 
induce the production of autoantibodies that contribute to experimental arthritis 
(82). In addition, IL-21, a product of Th17 cells, contributes to the IL-6-mediated 
antibody response (83). In addition, IL-17 has been shown to stimulate class-
switching in response to infection (84). Furthermore, B. burgdorferi-primed T cells 
have been shown to influence borreliacidal antibody production (85). However, 
the role of IL-17 in the antibody response to B. burgdorferi is not fully known.  
 
49 
 
As stated above, the effects of viable B. burgdorferi infection, as opposed to non-
viable infection, on IL-17 production during peak swelling were investigated. 
Surprisingly, whole lymph node cells from Borrelia-vaccinated mice infected with 
live B. burgdorferi 297, restimulated with B. burgdorferi 297, produced less IL-17 
than stimulated cells obtained from vaccinated mice injected with heat-killed 
organisms. This unexpected result may have occurred due to significant priming 
of borreliacidal antibody-producing B cells in vaccinated mice given a live 
infection. It was hypothesized that the in vitro exposure to B. burgdorferi 
stimulated a strong borreliacidal response in those vaccine-primed cells that had 
already interacted with B. burgdorferi 297 in vivo. These antibodies would have 
cleared the in vitro infection, removing the stimulus for IL-17 production. Since 
unseparated lymph node populations were used to assess cytokine levels in 
these mice, the association of IL-17 with development of the borreliacidal 
antibody response was investigated.   
 
B. burgdorferi 297-stimulated cells from Borrelia-vaccinated, non-infected mice 
produced low levels of borreliacidal antibodies (Figure 11). Unexpectedly, 
supernatants of restimulated cells from Borrelia-vaccinated mice injected with 
either viable or heat-killed B. burgdorferi 297 revealed high levels of borreliacidal 
antibody production (Figure 11). Unfortunately, whether or not the titers differed 
between these groups could not be determined, as the titers exceeded the level 
of detection in the assay. While these antibodies are stimulated by the presence 
of heat-killed bacteria, these results may also indicate that live infection induced 
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the production of borreliacidal antibodies which prevented a robust IL-17 
response in the in vitro system used here. Although stimulation of cells obtained 
from mice injected with heat-killed organisms also induced a high titer, an IL-17 
response also developed. These cells may have initially produced borreliacidal 
antibodies only upon primary exposure to live organism in vitro, while the cells 
from mice infected with live organism had already been producing these 
antibodies in vivo for 10 days. If this is the case, it is possible that the IL-17 
response developed prior to the significant production of protective antibodies, 
and that the prior existence of these antibodies inhibited the IL-17 response.  
 
Th17 cells may also contribute to the development of borreliacidal antibodies. IL-
6, a cytokine that supports Th17 cell differentiation (86), promotes the production 
of borreliacidal antibodies against immunodominant Borrelia epitopes in vitro (87, 
88). In addition, borreliacidal antibody titers are increased following in vitro 
neutralization of IFN-γ (89), which appears to be antagonistic to IL-17 in Lyme 
arthritis. It is shown here that Borrelia-infected mice treated with anti-IFN-γ 
antibodies produced more IL-17 during peak swelling, which may suggest that 
the corresponding increase in IL-17 may also contribute to borreliacidal antibody 
production. By contrast, treatment of Borrelia-vaccinated and -infected mice with 
antibodies against combinations of IL-17, IL-6, and TGF-β yielded borreliacidal 
antibody titers that did not fully correlate with disease outcome (45). Therefore, 
the timing of borreliacidal antibody production and induction of IL-17 may 
coincide, and each may affect the other. 
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Here, lower titers of borreliacidal antibodies in naïve wild-type mice, compared to 
naïve IL-10 KO mice, were observed (Figure 12). The increased levels of 
antibodies observed in the serum of IL-10 KO mice, despite lack of previous 
exposure to the organism, demonstrate the significance of IL-10 in borreliacidal 
antibody production. IL-10 KO mice also produced significantly greater levels of 
borreliacidal antibodies than their wild-type counterparts in the Borrelia-
vaccinated, non-infected group (Figure 12). These results are consistent with 
data demonstrating that large amounts of IL-10 suppress the proliferation and 
differentiation of certain types of B cells (90). Previous research has also shown 
that deficiency of IL-10 leads to increased borreliacidal antibody titers in vivo 
following infection with B. burgdorferi (80). However, these researchers reported 
that increased microbial clearance resulted from an enhanced innate immune 
response, rather than from the increased titers of borreliacidal antibodies (80). 
These findings are also consistent with our results. If IL-10 increases 
borreliacidal antibody production and IL-17 production, this IL-17 may also be 
produced by activated innate cells, including populations of neutrophils, dendritic 
cells, and/or natural killer cells. This is plausible, since it is shown here that cells 
other than CD4+ cells produce IL-17, as blocking CD4 did not completely inhibit 
production of the cytokine. 
 
In summary, the working hypothesis for this aim was increases in IL-17 are 
associated with an increase in borreliacidal antibody titers following infection with 
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B. burgdorferi. The data shown here partially support this hypothesis; however, 
an association between IL-17 and borreliacidal antibodies induced following 
infection of mice with live or dead B. burgdorferi was unable to be established. 
This may be due to the fact that the borreliacidal antibody titers exceeded the 
detection ability of the assay. This detection ability can be remedied in the future 
by creating additional dilutions for examination. In addition, infected IL-10 KO 
mice produced greater amounts of borreliacidal antibody and possessed cells 
that produced greater amounts of IL-17 upon in vitro culture. While an 
association can be made between increased IL-17 and increased borreliacidal 
antibodies, it is likely that the genetic deficiency in IL-10 is the major contributor.  
 
However, an association between IL-17 and borreliacidal antibody production 
may be observed in the wild-type mice used here. , In vitro-stimulated cells from 
Borrelia-vaccinated, non-infected wild-type mice produced larger amounts of IL-
17 than stimulated naïve cells and stimulated cells from Borrelia-infected mice 
after 24 hours of incubation (Figure 5). These mice also had significantly higher 
serum borreliacidal antibody titers than either group (Figure 12). However, while 
Borrelia-vaccinated and -infected wild-type mice produced high borreliacidal 
antibody titers than other groups (Figure 12), stimulated, unseparated lymph 
node cells from these mice produced lower-than-expected amounts of IL-17 
(Figure 5). This may be due to the presence of the borreliacidal antibodies in the 
in vitro cultures, showing that a relationship between borreliacidal antibodies and 
IL-17 production may exist. A future study to further examine this relationship 
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would be to administer anti-IL-17 antibodies to wild-type and IL-10 KO mice using 
both of these Lyme arthritis models, and then observe the borreliacidal antibody 
response. A previous investigation of this, using wild-type C57BL/6 mice, B. 
burgdorferi 297 as the vaccine strain, and B. bissettii as the infection strain, led 
inconclusive results pertaining to a relationship between borreliacidal antibody 
titers and the presence of Th17 cytokines (45). However, in that study, blocking 
IL-17 and the Th17-differentiating cytokines IL-6 and TGF-β completely inhibited 
the borreliacidal antibody response, demonstrating that Th17 cells and 
borreliacidal antibody production may be linked. Further studies are needed to 
further elucidate the relationship between IL-17 and the production of 
borreliacidal antibodies.. 
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CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS 
The hypothesis for this thesis was that IL-17 produced by CD4+ cells contributes 
to the inflammation associated with B. burgdorferi infection and is associated with 
an increase in borreliacidal antibody production. The first aim, to establish CD4+ 
cells as a source of IL-17 following infection with B. burgdorferi, was supported. 
Using different models of Lyme arthritis, the data presented here supported 
known relationships between Th1 and Th17 cells as well as between IL-10 and 
Th17 cells. Production of IL-17 increased following B. burgdorferi infection and 
was prominent at the peak of hind paw swelling. At this peak swelling period, IL-
17 production was regulated by both IFN-γ and IL-10, and was produced, in part, 
by CD4+ cells. It is likely that Th17 cells are contributing to the development of 
Lyme arthritis through their production of IL-17. The second specific aim, which 
was to establish a relationship between IL-17 levels and borreliacidal antibody 
production, was partially supported. As levels of IL-17 increased in both wild-type 
mice and IL-10 KO mice infected with B. burgdorferi, an increase in the 
production of borreliacidal antibodies was observed. However, additional 
research is required to better characterize the role of IL-17 in this process.  
 
Overall, these findings provide additional evidence to support consideration of 
inflammatory cytokines other than IFN-γ as contributors to Lyme arthritis 
following infection with B. burgdorferi. This may lead to new targets for therapy 
against Lyme arthritis. One future study to more directly examine the role of IL-17 
following B. burgdorferi infection will be conducted by administering anti-IL-17 
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antibodies to wild-type and IL-10 KO mice using both the Borrelia-infection and 
Borrelia-vaccination and -infection Lyme arthritis models, and then observing the 
borreliacidal antibody response and joint histopathology that result. Future 
studies are also needed to determine the role of additional sources of IL-17, 
including neutrophils and γδ-T cells (21, 69), following borrelial infection. In     
addition, experiments are planned to determine the actual abundance of Th17 
cells in B. burgdorferi-infected mice and to determine their contribution to Lyme 
arthritis.  
 
However, recent findings show that T cell populations are not as well defined as 
is commonly presented, which confounds investigations pertaining to Th17 cells. 
Depending on the cytokine environment during development, Th17 cells are able 
to convert into both Th1- and Treg-like cells (52). For example, some Th17 cells 
may also produce IFN-γ, giving them characteristics of Th1 cells. IL-17+IFN-γ+ 
Th17 cells are more prominent in autoimmune diseases and, perhaps not 
surprisingly, suppress traditional IL-17+IFN-γ- Th17 cells (91). In addition, 
populations of Th17 cells can also produce IL-10 (52), thereby potentially 
regulating the immune response in the same manner as Treg cells. Future studies 
will require consideration of these newly discovered T cell phenotypes in 
investigation of B. burgdorferi infection and Lyme arthritis. Importantly, this also 
opens a line of research into the modulation of T cells for therapy for, or 
prevention of, Lyme arthritis.  
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The findings presented here support a potential role for Treg cells in the regulation 
of Lyme arthritis. Specifically, CD4+CD25+Foxp3+ Treg cells are critical for 
maintaining tolerance and managing autoimmune diseases, in part, through 
secretion of IL-10 (92). Bettelli et al. (44) published the major finding that Th17 
and CD4+CD25+Foxp3+ regulatory T cells are derived from a common precursor 
T cell, with the presence or absence of a certain inflammatory cytokine 
environment determining the outcome of differentiation. Prior to this finding, an 
association between IL-17 and presumed Treg cells was described in the 
development and regulation of Lyme arthritis, using IFN-γ-deficient, Borrelia-
vaccinated and -infected mice (49). Neutralization of IL-17 in these mice, in 
addition to preventing the development of arthritis, led to an increase in the 
numbers of CD4+CD25+ T cells in the local lymph nodes (49). Depletion of 
CD25+ cells in anti-IL-17 antibody-treated, Borrelia-vaccinated and -infected 
mice led to severe, destructive arthritis (49). In addition, transfer of CD4+CD25+ 
cells obtained from these anti-IL-17 antibody-treated mice into infected recipient 
mice protected against arthritis development (93). By contrast, transfer of 
CD4+CD25- T cells into infected recipients increased disease severity (93). 
Moreover, depletion of CD4+CD25+ T cells in Borrelia-vaccinated and -infected 
mice not administered anti-IL-17 antibodies did not affect arthritis (94), 
suggesting that the absence of IL-17 induced a distinct subpopulation of 
CD4+CD25+ T cells that protected against the induction of Lyme arthritis.  
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Additional data support a role for Treg cells (and, by extension, Th17 cells), in 
Lyme arthritis. Mice deficient in CD28, a co-stimulatory molecule for Treg cells, 
displayed intensified and chronic arthritis in response to infection with B. 
burgdorferi (95). Shorter duration to resolution of disease has also been 
associated with higher percentages of Treg cells in patients with Lyme arthritis 
(28). By contrast, patients with antibiotic-refractory Lyme arthritis had lower 
percentages of Treg cells and displayed an inability to resolve synovial 
inflammation (28). However, Kuo et al. demonstrated that administration of 
recombinant interleukin 35 (IL-35), another anti-inflammatory cytokine produced 
by Treg cells, to B. burgdorferi-vaccinated and -infected mice actually increased 
the severity of Lyme arthritis and decreased borreliacidal antibody titers (96). 
Collectively, these findings point to Treg cells as a significant factor in the 
regulation of Lyme arthritis. Since Th17 cells are closely related to these cells, 
investigation of both cell types is needed for a complete examination of the 
immune response to B. burgdorferi infection. 
 
Due to the large increases in production of IL-17 after 24 hours of cell culture by 
the cells obtained at the peak of hind paw swelling shown here, it is also 
important to consider the production of the cytokine at earlier time points in the 
development of arthritis. Preliminary data indicate that IL-17 may play a 
significant role early in infection. Cells obtained from mice one day after infection 
produced significant levels of IL-17 (data not shown). These levels were reduced 
upon addition of anti-CD4 antibody, regardless of infection model (data not 
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shown). Incubation of stimulated cells with anti-CD4 antibody also reduced IFN-γ 
in these cells (data not shown), further demonstrating that both inflammatory 
cytokines may contribute to Lyme arthritis.   
Understanding the immune mechanisms of Lyme arthritis, particularly the role of 
IL-17, is necessary for the development of safe vaccines for Lyme borreliosis. 
Currently, OspA and outer surface protein C (OspC) are the most commonly 
considered vaccine candidates for Lyme borreliosis. While OspA has been 
shown to induce borreliacidal antibody titers, it may also induce an autoimmune 
response (57). In fact, Croke et al. showed that vaccination of hamsters with 
OspA primed the animals for development of severe Lyme arthritis following 
infection with B. burgdorferi (97). These findings fueled concern regarding the 
safety of OspA vaccines in humans (64). The data presented here suggest that a 
successful vaccinate candidate needs to elicit high borreliacidal antibodies titers 
without inducing an IL-17 response in order to confer immunity without the 
induction of arthritis.   
 
In conclusion, IL-17 has been shown to play a role in the development of Lyme 
arthritis. Here, a role for CD4+ cells as a major producer of IL-17 following 
infection with B. burgdorferi is supported. Additionally, a relationship between IL-
17 and borreliacidal antibodies may exist. Future studies will be needed to more 
completely characterize the immune response to B. burgdorferi and the 
development of Lyme arthritis. However, the findings presented here have 
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significant implications for the development of both therapeutic interventions and 
safe, effective vaccines against Lyme borreliosis.   
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